-
91.发明申请公开(公告)号：US20210283231A1
公开(公告)日：2021-09-16
申请号：US17333994
申请日：2021-05-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
92.发明申请
公开(公告)号：US20210277081A1
公开(公告)日：2021-09-09
申请号：US17314629
申请日：2021-05-07
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20210275652A1
公开(公告)日：2021-09-09
申请号：US17314492
申请日：2021-05-07
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Colette SONG
IPC: A61K39/00 , G16B25/00 , C07K14/47 , A61P35/00 , A61K35/17 , C07K16/18 , C12N5/0783 , C12N15/115 , C07K14/74 , C07K16/28 , C07K16/30
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20210268089A1
公开(公告)日：2021-09-02
申请号：US17245918
申请日：2021-04-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sarah KUTSCHER
IPC: A61K39/00 , A61K38/04 , C07K7/06 , C07K7/00 , C07K7/08 , A61K35/17 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , C07K14/435 , C07K14/725 , C07K14/74
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.
-
公开(公告)号：US20210093702A1
公开(公告)日：2021-04-01
申请号：US17116845
申请日：2020-12-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Claudia WAGNER , Julia LEIBOLD , Colette SONG
IPC: A61K39/00 , A61P35/00 , G16B20/20 , A61K35/17 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
96.发明申请
公开(公告)号：US20200338175A1
公开(公告)日：2020-10-29
申请号：US16915323
申请日：2020-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Jens FRITSCHE , Harpreet SINGH , Andrea MAHR , Martina OTT , Claudia WAGNER , Oliver SCHOOR
IPC: A61K39/00 , C12N15/115 , C07K14/47 , C07K16/18 , C07K14/74
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
97.发明申请
公开(公告)号：US20200323967A1
公开(公告)日：2020-10-15
申请号：US16915283
申请日：2020-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/74 , C07K16/28 , C12N15/115 , C12N5/0783 , A61K35/17 , A61K38/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
98.发明申请
公开(公告)号：US20200308250A1
公开(公告)日：2020-10-01
申请号：US16900542
申请日：2020-06-12
Applicant: immatics biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH , Lea STEVERMANN
IPC: C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
99.发明申请
公开(公告)号：US20200164053A1
公开(公告)日：2020-05-28
申请号：US16752156
申请日：2020-01-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni WEINSCHENK , Helen HOERZER , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , A61P35/00 , C07K14/72 , C07K16/00 , C07K16/28 , A61K35/17 , A61K38/08 , A61P35/02 , C12N15/115 , C07K14/725 , C07K14/47 , C07K7/06 , A61K38/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
100.发明申请
公开(公告)号：US20200138924A1
公开(公告)日：2020-05-07
申请号：US16669192
申请日：2019-10-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea MAHR , Toni Weinschenk , Anita Wiebe , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , A61K35/17 , A61K38/08 , C12N5/0783 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/74 , C07K16/28 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
